Treatment of BRAF-mutation-positive unresectable or metastatic malignant melanoma has been transformed in recent years by the identification of BRAFmutations and the development of BRAF and MEK inhibitors, as well as by establishing the disease’s immunogenic properties and subsequent immunotherapy advances. Despite the remarkable OS and PFS data demonstrated by some of the new therapies, the prevailing unmet needs in the treatment of BRAF-mutation-positive unresectable or metastatic malignant melanoma focus on further improvements in OS and PFS against current therapies, which continue to be sought by physicians and regulatory authorities alike. Other key efficacy challenges are to overcome the relatively low ORR associated with immunotherapies and to overcome the relatively short DoR associated with BRAF and MEK inhibitors. Minimizing the incidence of treatment-related toxicities, particularly the incidence of immune-related AEs, is another important unmet need in BRAF-mutation-positive unresectable or metastatic malignant melanoma.

Questions Answered:

  • What are the treatment drivers and goals for BRAF-mutation-positive unresectable or metastatic malignant melanoma?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for BRAF-mutation-positive unresectable or metastatic malignant melanoma?
  • What are the prevailing areas of unmet need and opportunity in BRAF-mutation-positive unresectable or metastatic malignant melanoma?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new BRAF-mutation-positive unresectable or metastatic malignant melanoma drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in January 2017.

Key companies: Bristol-Myers Squibb, Novartis, Merck

Key drugs: Opdivo, Yervoy, Tafinlar


Related Reports

Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast

The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/ME...

View Details

Malignant Melanoma | Disease Landscape and Forecast | G7 | 2020

The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combination regimens, such as Roche /...

View Details

Malignant Melanoma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of ma...

View Details

Malignant Melanoma - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key endometrial cancer pati...

View Details